Solésence details $366,912 severance package for former CEO

Solésence, Inc. disclosed details of a separation agreement with former CEO Jess Jankowski following his previously reported resignation as an officer.

Rhea-AI Filing Summary

Solésence, Inc. disclosed details of a separation agreement with former CEO Jess Jankowski following his previously reported resignation as an officer. Under the agreement, effective December 2, 2025, Jankowski will receive severance pay totaling $366,912, accelerated vesting of all his outstanding stock options, and continued company-paid health insurance premiums under COBRA for the duration of the severance period. In return, he is providing a broad release of claims against the company and reaffirming obligations such as restrictive covenants and assistance in certain potential disputes. The separation agreement is filed as an exhibit to this report, with some portions redacted as confidential.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Solésence (SLSN) announce in this 8-K filing?

Solésence, Inc. announced that it entered into a Separation Agreement and General Release with former CEO Jess Jankowski, detailing his severance and related terms following his resignation as an officer.

How much severance is Solésence (SLSN) paying former CEO Jess Jankowski?

Under the separation agreement, former CEO Jess Jankowski will receive severance pay totaling $366,912.

What equity-related benefits does Jess Jankowski receive from Solésence (SLSN)?

The agreement provides for accelerated vesting of all outstanding stock options previously granted to Jess Jankowski.

How will Solésence (SLSN) handle health insurance for former CEO Jess Jankowski?

For the period during which severance is paid, Solésence will pay the monthly insurance premiums for Jess Jankowski’s participation in the company’s group health insurance plan through COBRA.

What does Jess Jankowski agree to in exchange for the Solésence (SLSN) separation benefits?

In exchange, Jess Jankowski agrees to release all claims against Solésence and its representatives, continue complying with restrictive covenants, and assist the company, at its request, in certain potential disputes.

Where can investors find the full terms of the Solésence (SLSN) separation agreement?

The full terms are in Exhibit 10.1 to the report, titled “Confidential Separation Agreement and Release, dated November 24, 2025,” with some confidential portions redacted.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/02/2025 - 07:11 PM Learn about SEC filing dates

false 0000883107 0000883107 2025-11-24 2025-11-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): (November 24, 2025)

SOLESENCE, INC

(Exact name ofregistrant as specified in its charter)

Delaware	0-22333	36-3687863
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.

1319 Marquette Drive

Romeoville, Illinois 60446

(Address of Principal Executive Offices) (Zip Code)

(630) 771-6708

(Registrant's telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value per share	SLSN	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

lfan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

The Company previously reported on a Current Report on Form 8-K dated December 1, 2025 that former CEO, Jess Jankowski had resigned as an officer of the Company. Subsequently, the Company entered into a Separation Agreement and General Release of All Claims, effective as of December 2, 2025, with Mr. Jankowski (the "Separation Agreement"). Pursuant to the Separation Agreement, Mr. Jankowski will receive severance pay in the aggregate gross amount of $366,912. Mr. Jankowski will also receive accelerated vesting of all outstanding options previously granted to Mr. Jankowski. Furthermore, during the period severance will be paid, the Company will pay the monthly insurance premiums for Mr. Jankowski's participation in the Company's group health insurance plan through COBRA. In consideration of these and other benefits provided under the Separation Agreement, Mr. Jankowski agreed to release any and all claims against the Company and its representatives and confirmed his continuing obligations to the Company including compliance with certain restrictive covenants and assisting the Company, at its request, in certain potential disputes. The Separation Agreement is filed hereto as Exhibit 10.1 and is incorporated herein by reference. The descriptions thereof contained in this Form 8-K are qualified in all respects by the terms and provisions of the Separation Agreement.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
10.1		Confidential Separation Agreement and Release, dated November 24, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

* Confidential portions of this exhibit have been redacted.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 2, 2025

	SOLÉSENCE, INC.
	By:	/s/ Laura Riffner
		Name: Laura Riffner
		Title: CFO